A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Medial Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
- Registry ID
- EUCTR2006-001913-13
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE3
- Sponsor
- Merck & Co., Inc.
- Start date
- 2006-11-29
- Completion date
- 2008-05-20
- Last update
- 2026-08-16
Conditions
- heterozygous familial hypercholesterolemia (HeFH)
Summary
In patients with heterozygous familial hypercholesterolemia (HeFH): (1) To demonstrate the effects of MK-0524A coadministered with intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy compared to intensive LDL C lowering therapy alone on atherosclerosis progression as measured with non-invasive B-mode ultrasound carotid artery intima medial thickening (cIMT) measurements.
Locations
- , , UK
- , , Germany
- , , France
- , , Sweden
View on source registry